7668-87-3

Usage

InChI:InChI=1/C21H27NO6/c1-24-16-7-6-14(10-17(16)25-2)8-9-22-20(23)13-15-11-18(26-3)21(28-5)19(12-15)27-4/h6-7,10-12H,8-9,13H2,1-5H3,(H,22,23)

Upstream product

• 951-82-6 3,4,5-trimethoxyphenyl acetic acid 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 39053-78-6 3,4,5-trimethoxyphenylacetyl chloride 

Downstream Products

• 73554-57-1 6,7-dimethoxy-1-(3',4',5'-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 76129-86-7 N-formyl-6,7-dimethoxy-1-(3',4',5'-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 61349-11-9 1-(3',4',5'-trimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinoline 
• 53392-39-5 6,7-dimethoxy-1-(3', 4', 5'-trimethoxybenzyl)2-methyl, 3,4-dihydroisoquinolinium iodide 
• 108704-76-3 6,7-dimethoxy-1-(3,4,5-trimethoxybenzyl)-3,4-dihydroisoquinoline hydrochloride 
• 188956-91-4 (R)-6,7-dimethoxy-1-(3',4',5'-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 104832-01-1 (R)-N-methyl-6,7-dimethoxy-1-(3',4',5'-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinium 2,3-dibenzoyl-L-tartarate 
• 24734-71-2 N-methyl-6,7-dimethoxy-1-(3',4',5'-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 7668-88-4 rac-6,7-dimethoxy-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 64229-10-3 C₅₂H₇₀N₂O₁₄⁽²⁺⁾*2CH₃O₃S^(1-) 
• 81165-39-1 3-[6,7-Dimethoxy-1-(3,4,5-trimethoxy-benzyl)-3,4-dihydro-1H-isoquinolin-2-yl]-propionic acid 2-{3-[6,7-dimethoxy-1-(3,4,5-trimethoxy-benzyl)-3,4-dihydro-1H-isoquinolin-2-yl]-propionyloxy}-ethyl ester; compound with oxalic acid 

Relevant academic research and scientific papers

Effect of 1-Substitution on Tetrahydroisoquinolines as Selective Antagonists for the Orexin-1 Receptor

Selective blockade of the orexin-1 receptor (OX1) has been suggested as a potential approach to drug addiction therapy because of its role in modulating the brain's reward system. We have recently reported a series of tetrahydroisoquinoline-based OX1 selective antagonists. Aimed at elucidating structure-activity relationship requirements in other regions of the molecule and further enhancing OX1 potency and selectivity, we have designed and synthesized a series of analogues bearing a variety of substituents at the 1-position of the tetrahydroisoquinoline. The results show that an optimally substituted benzyl group is required for activity at the OX1 receptor. Several compounds with improved potency and/or selectivity have been identified. When combined with structural modifications that were previously found to improve selectivity, we have identified compound 73 (RTIOX-251) with an apparent dissociation constant (Ke) of 16.1 nM at the OX1 receptor and >620-fold selectivity over the OX2 receptor. In vivo, compound 73 was shown to block the development of locomotor sensitization to cocaine in rats. (Chemical Equation Presented).

Two optimized synthetic pathways toward a chiral precursor of Mivacurium chloride and other skeletal muscle relaxants

A chiral precursor of Mivacurium chloride, (R)-5′-methoxylaudanosine, was prepared using two different methods. The chiral resolution of racemic 5′-methoxylaudanosine, typically used in industry, was carried out in parallel with a procedure consisting of

Novel hybrids from lamellarin D and combretastatin A 4 as cytotoxic agents

A new series of hybrids of lamellarin D and combretastatin A 4, 1,2-diphenyl-5,6-dihydropyrrolo [2,1-a] isoquinolines, were designed as cytotoxic agents based on principles of combination in medicinal chemistry and taking the parent compounds' different anti-proliferative mechanisms into consideration. Twenty-two novel hybrids were synthesized through a convenient route, with a key step of core pyrrole formation and evaluated for their anti-proliferative activities in vitro against K-562, A-549, SMMC-7721, SGC-7901 and HCT-116 cancer cell lines. The results showed that some hybrids had good anti-proliferative activities in low IC50 ranges.

Studies on Protoberberine Alkaloids : Synthesis of Glabrine Dimethyl Ether

2,3,9,10,11-Pentamethoxyprotoberberinium salt (III) has been synthesized from homoveratrylamine and 3,4,5-trimethoxyphenylacetic acid through the intermediacy of an N-formyl-benzyltetrahydroisoquinoline derivative (VI).The synthetic material is identical

Bis-isoquinolinium compounds, compositions and methods of use

Intermediate-duration reversible neuromuscular blocking agents of the formula (I) STR1 where B and C are preferably para or may be meta and are each STR2 where W is CH2 or most preferably CH=CH R1, R2, R3 and R

Neuromuscular blocking agents

Short acting reversible neuromuscular blocking agents of the formula (I) STR1 where B and C is preferably meta or maybe para STR2 where m is 2, 3 or 4 and is preferably 2, R1, R2, R3, R4, R5, R6 and R7 are the same or different and are hydrogen or lower alkoxy of 1 to 4 carbon atoms Y is lower alkyl of 1 to 4 carbon atoms n is 2, 3 or 4, most preferably 3, provided that at least one of R1 to R4 and one of R5 to R7 is lower alkoxy and X is a pharmaceutically acceptable anion. These neuromuscular blocking agents of formula I are useful upon administration to a patient in providing muscular relaxation in the patient during surgery and are normally intravenously administered in a pharmaceutically acceptable carrier.